MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease

University of Aarhus1 site in 1 country21 target enrollmentDecember 22, 2022

ConditionsAlzheimer Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alzheimer Disease
Sponsor: University of Aarhus
Enrollment: 21
Locations: 1
Primary Endpoint: Deuterium Metabolic Imaging
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.

Registry

clinicaltrials.gov

Start Date

December 22, 2022

End Date

October 27, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Aarhus

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Deuterium Metabolic Imaging

Time Frame: Up to 150 mins after 2H-glucose ingestion

Lactate/glx ratio in the posterior cingulum (sub-study 2).

Secondary Outcomes

Deuterium Metabolic Imaging(Up to 150 mins after 2H-glucose ingestion)
FDG-PET from the records (sub study 2)(At time of Deuterium Metabolic Imaging)
Blood samples(Up to 150 mins after 2H-glucose ingestion)
Cognitive tests from the records (sub study 2)(At time of Deuterium Metabolic Imaging)
Cerebrospinal fluid biochemistry from the records (sub study 2)(At time of Deuterium Metabolic Imaging)